Immatics N.V. (IMTX)

NCM – Real vaqt narxi. Valyuta: USD

11.39

-0.15 (-1.30%)

Yopilishda: May 12, 2026, 4:00 PM EDT

11.39

0.00 (0.00%)

Bozordan keyin: May 12, 2026, 5:42 PM EDT

06.05.2026

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy

Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

21.04.2026

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced all submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois, USA.

09.03.2026

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot

Immatics (IMTX) remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline. IMTX's valuation reflects high expectations, with the PRAME franchise and next-generation assets like IMA402 representing key upside optionality. SUPRAME's mid-2026 interim update is a pivotal go/no-go catalyst, but unlikely to deliver a near-term stock-moving data readout.

25.12.2025

Immatics: PRAME Leader's Transition To Commercial Reality

Immatics executes a three-wave strategy, progressing from melanoma treatment to broader solid tumors and scalable bispecific TCR therapeutics. IMTX's $505.8M cash position funds operations through 2027, covering BLA submission and anticipated commercial launch, reducing near-term financing risk. Anzu-cel's Phase 3 SUPRAME trial and IMA203CD8's promising ovarian cancer data support a robust, expanding clinical pipeline with significant addressable markets.

11.12.2025

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Houston , Texas and Tuebingen, Germany, December 11, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced updated Phase 1a dose escalation data from its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated patients with solid tumors. Based on the enhanced pharmacology of IMA203CD8 reported previously, IMA203CD8 provides the potential to address difficult-to-treat solid tumors expressing PRAME beyond melanoma, such as ovarian cancer.

05.12.2025

Immatics Announces $125 Million Underwritten Offering

Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125 million. The offering is expected to close on December 8, 2025, subject to customary closing conditions.

17.11.2025

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

Immatics (IMTX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.12 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

21.04.2026

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

11.12.2025

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

05.12.2025

Immatics Announces $125 Million Underwritten Offering

12.11.2025

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET

Immatics N.V. (IMTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immatics N.V. (IMTX)

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot

Immatics: PRAME Leader's Transition To Commercial Reality

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics Announces $125 Million Underwritten Offering

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

Videolar

No Data

Press-relizlar

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics Announces $125 Million Underwritten Offering

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot

Immatics: PRAME Leader's Transition To Commercial Reality

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics Announces $125 Million Underwritten Offering

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

Videolar

No Data

Press-relizlar

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics Announces $125 Million Underwritten Offering

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

Search stocks

Immatics N.V. (IMTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immatics N.V. (IMTX)

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot

Immatics: PRAME Leader's Transition To Commercial Reality

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics Announces $125 Million Underwritten Offering

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

Videolar

No Data

Press-relizlar

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics Announces $125 Million Underwritten Offering

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot

Immatics: PRAME Leader's Transition To Commercial Reality

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics Announces $125 Million Underwritten Offering

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

Videolar

No Data

Press-relizlar

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics Announces $125 Million Underwritten Offering

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps